{
    "clinical_study": {
        "@rank": "136267", 
        "arm_group": [
            {
                "arm_group_label": "BI 655075 single doses", 
                "arm_group_type": "Experimental", 
                "description": "different infusion durations"
            }, 
            {
                "arm_group_label": "BI 655075 with dabigatran", 
                "arm_group_type": "Experimental", 
                "description": "short infusion with 2 capsules dabigatran"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI\n      655075 following intravenous administration of single rising doses of BI 655075 when\n      administered alone and after administration of dabigatran."
        }, 
        "brief_title": "Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. Healthy Japanese male subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028780", 
            "org_study_id": "1321.5"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 655075 with dabigatran", 
                "description": "short infusion", 
                "intervention_name": "BI 655075", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 single doses", 
                "description": "placebo", 
                "intervention_name": "Placebo to dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 with dabigatran", 
                "description": "Placebo to BI 655075", 
                "intervention_name": "Placebo to BI 655075", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 with dabigatran", 
                "description": "2 capsules dabigatran", 
                "intervention_name": "dabigatran", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 single doses", 
                "description": "different infusion durations", 
                "intervention_name": "BI 655075", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sumida-ku, Tokyo", 
                    "country": "Japan"
                }, 
                "name": "1321.5.00001 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2).", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The number (%) of subjects with drug-related adverse events in Part 1 and Part 2", 
            "safety_issue": "No", 
            "time_frame": "up to 108 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028780"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "sum dabigatran: Ae0-72 in Part 2", 
                "safety_issue": "No", 
                "time_frame": "from Day 4 to Day 7"
            }, 
            {
                "measure": "sum dabigatran: Ae0-72 in Part 2", 
                "safety_issue": "No", 
                "time_frame": "from Day 11 to Day 14"
            }, 
            {
                "measure": "unbound sum dabigatran: AUC2-12 (area under the concentration-time curve of the analyte in plasma over the time interval from 2 hour - 72 hour) in Part 2", 
                "safety_issue": "No", 
                "time_frame": "from Day 4 to Day 7"
            }, 
            {
                "measure": "unbound sum dabigatran: AUC2-12 in Part 2", 
                "safety_issue": "No", 
                "time_frame": "from Day 11 to Day 14"
            }, 
            {
                "measure": "dTT (diluted thrombin time): AUEC2-12 in Part 2", 
                "safety_issue": "No", 
                "time_frame": "from Day 4 to Day 7"
            }, 
            {
                "measure": "dTT: AUEC2-12 in Part 2", 
                "safety_issue": "No", 
                "time_frame": "from Day 11 to Day 14"
            }, 
            {
                "measure": "BI 655075: Cmax (maximum measured concentration of the analyte in plasma) in Part 1 and Part 2", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days"
            }, 
            {
                "measure": "BI 655075: AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) in Part 1 and Part 2", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days"
            }, 
            {
                "measure": "BI 655075: Ae0-72 (amount of the analyte excreted in urine over the time interval from 0 to 72 hour) in Part 1 and Part 2", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}